Valuation: Allogene Therapeutics, Inc.

Market Cap 59Cr 52Cr 49Cr 44Cr 83Cr 5.65TCr 83Cr 582.38Cr 224.72Cr 2.88TCr 221.87Cr 217Cr 9.3TCr P/E 2026 *
-2.83x
P/E 2027 * -2.66x
Enterprise Value 39Cr 34Cr 32Cr 30Cr 55Cr 3.77TCr 55Cr 388.65Cr 149.97Cr 1.92TCr 148.06Cr 144.82Cr 6.21TCr EV / Sales 2026 *
116x
EV / Sales 2027 * 36.5x
Free-Float
83.55%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week+0.30%
Current month-15.25%
1 month-16.50%
3 months-18.12%
6 months-30.53%
Current year+23.72%
1 week 1.64
Extreme 1.645
1.76
1 month 1.64
Extreme 1.645
2.21
Current year 1.31
Extreme 1.31
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
27.64
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 01/07/2026
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 66 01/06/2018
Director/Board Member 49 01/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Sell

Compliance Officer

-29,697 0.0086%
01/07/26 Free

Chief Executive Officer

6,10,720 0.1769%
18/06/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+0.30%+44.87%-51.71% 59Cr
-0.07%+7.14%+53.95%+111.00% 7.43TCr
-1.29%-0.47%+34.70%+76.99% 6.12TCr
+0.28%+5.73%+33.67%+20.82% 2.75TCr
+0.86%-1.77%-17.18%+367.07% 2.64TCr
-0.00%+5.09%+2.48%-2.34% 2.53TCr
+1.80%+4.84%+27.01%-8.05% 2.08TCr
-1.47%+4.86%-5.94%+519.63% 1.49TCr
+0.87%-3.73%+159.95%+327.53% 1.52TCr
-0.58%+1.32%+44.51%+163.54% 1.44TCr
Average -0.03%+2.80%+37.80%+152.45% 2.81TCr
Weighted average by Cap. -0.10%+3.43%+36.47%+135.54%

Financials

2026 *2027 *
Net sales 34L 29.71L 27.93L 25.48L 47.83L 33Cr 47.84L 3.35Cr 1.29Cr 17Cr 1.28Cr 1.25Cr 54Cr 1.21Cr 1.06Cr 99.27L 90.59L 1.7Cr 115.54Cr 1.7Cr 12Cr 4.6Cr 59Cr 4.54Cr 4.44Cr 190.21Cr
Net income -19Cr -16Cr -15Cr -14Cr -26Cr -1.77TCr -26Cr -182.51Cr -70Cr -903.85Cr -70Cr -68Cr -2.91TCr -22Cr -19Cr -18Cr -16Cr -31Cr -2.1TCr -31Cr -216.71Cr -84Cr -1.07TCr -83Cr -81Cr -3.46TCr
Net Debt -20Cr -17Cr -16Cr -15Cr -28Cr -1.88TCr -28Cr -193.72Cr -75Cr -959.41Cr -74Cr -72Cr -3.09TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.44TCr -21Cr -148.03Cr -57Cr -733.12Cr -56Cr -55Cr -2.36TCr
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
23/26/23 $1.695 -0.88% 8,75,107
22/26/22 $1.710 +1.18% 52,37,474
21/26/21 $1.690 0.00% 59,92,401
18/26/18 $1.690 -2.31% 1,27,16,961
17/26/17 $1.730 +2.37% 39,48,057
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.710USD
Average target price
9.000USD
Spread / Average Target
+426.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!